RELI News & Events

Reliance Global Group announced that it has entered into a non-binding term sheet to acquire a controlling interest in Enquantum. In addition, in connection with the term sheet, On January 15, 2026, Reliance executed a secured promissory note as an advance of the initial funding under a definitive agreement, if executed. The Promissory Note is secured by all of the assets of Enquantum and payable within 60 days of its issuance date if a definitive agreement is not entered into. If a definitive agreement is entered into, the balance due under the Promissory Note will be applied against the first two payment milestones.

Reliance Global Group announced that its ticker symbol on the NASDAQ Capital Market will change from "RELI" to "EZRA", effective at the open of trading on Monday, January 26. The Company's common stock will continue to be listed on NASDAQ, and its CUSIP number will remain unchanged. The company said, "The ticker symbol change is intended to better reflect the Company's strategic evolution, including the formation of EZRA International Group, a new division focused on acquiring controlling stakes and accelerating the growth of breakthrough technology companies, with an initial emphasis on businesses operating across sectors such as cybersecurity, artificial intelligence and data analytics, FinTech and InsurTech, as well as MedTech and digital health. This strategic evolution is already underway through the Company's recently announced plan to acquire a majority stake in Scentech, an artificial intelligence diagnostics company developing non-invasive, breath-based disease-detection technologies. The proposed Scentech transaction, structured around clinical, regulatory, and operational milestones, represents the Company's first anticipated acquisition under EZRA International Group and reflects the Company's intention to pursue high-impact, technology-driven opportunities with significant long-term upside potential."

Reliance Global announced that it has entered into a non-binding term sheet to acquire a majority equity position of Scent Medical Technologies. Scentech is a diagnostics company developing artificial intelligence technologies designed to identify disease-associated molecular signatures in human breath. Scentech's product candidates are under development and have not yet been clinically validated or approved for commercial use. Any potential clinical or commercial outcomes remain subject to successful clinical validation and applicable regulatory clearances or approvals. The proposed transaction is expected to become the first asset within Ezra International Group, Reliance's newly established division focused on strategic investments in technology-driven companies.